CD19 and lymphopenia: A study on 25 patients with inoperable hepatic malignancies treated with TARE demonstrated that treated patients had a profound lymphopenia directly after therapy, whereas granulocytes and monocytes increased rapidly, leading to an overall increase in the total number of leukocytes; lymphopenia affected all subpopulations: CD3+, CD4+, CD8+ T cells, CD4+ CD8+ T cells, CD19+ B cells, and NK cells [126].